Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Pharmas Cleared Of Price-Fixing By U.K. Court

This article was originally published in PharmAsia News

Executive Summary

A U.K. court denied price-collusion allegations against five pharmaceuticals, including at least two with Indian ties. Goldshield, founded by India's Ajit Patel, and Ranbaxy U.K. were among firms that had been under investigation on price-fixing allegations for more than six years by the Serious Fraud Office. A U.K. court cleared the companies of a conspiracy allegation brought by the National Health Service concerning the prices of antibiotics and other common drugs. The court decided the allegations involved actions that allegedly occurred before the U.K. adopted a law making price-fixing an offense. (Click here for more

You may also be interested in...



Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay

Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.

ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel